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Abstract (150 words) 
 
Stillbirth is delivery of a baby at or after 24 weeks of gestational age (UK definition) showing no signs 
of life. It affects almost 1 in 200 pregnancies and is the single major cause of perinatal death. 
Stillbirth is associated with a wide range of maternal demographic characteristics, but most of the 
variation in stillbirth risk is independent of these characteristics. Stillbirth is the end point of multiple 
processes, but the single most common cause is probably placental dysfunction. Stillbirth is 
associated with a range of biochemical and ultrasonic predictors, but there is limited evidence to 
support population based screening. However, the evidence based is weak due by use of poorly 
characterised screening tests, the failure to couple risk assessment with a clearly effective 
intervention for those who screen positive, and inadequate study sample sizes. Basic research needs 
to identify better predictors, and clinical trials need to adopt more rigorous methodology. 
 
Key words: 
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1. Introduction 
The 2016 Lancet Ending Preventable Stillbirth Series indicated that the UK was in about the middle of 
the range of 49 high income countries in relation to stillbirth rates, and had one of the slowest rates 
of decline in stillbirth.1 The absolute risk of stillbirth from 24 weeks onwards is 3-5 per 1,000, i.e. 
about the same as the total risk of death in the first year of life. Moreover, a significant proportion of 
stillbirths potentially could have been prevented if the babies had been identified as high risk, i.e. 
cases where the cause of death was not a major congenital anomaly and where the death occurred 
at a gestational age associated with a low risk of infant mortality.2 A recent study, supported by the 
James Lind Alliance, reported the top research priorities in relation to stillbirth. This study elicited 
1275 responses from 574 participants (equally divided between professionals and non-professionals) 
and identified several priorities (out of 300 indicative unanswered questions) directly related to 
screening, (e.g. Priority #5, Does ultrasound assessment of fetal growth in the third trimester reduce 
stillbirth?), and 4 others which were also relevant (e.g. Priority #6, Would increasing the frequency 
of umbilical artery Doppler scanning during pregnancy reduce stillbirth?).3 The top 11 
recommendations are listed (Table 1). The aim of the current review is to consider current practice 
in relation to screening for stillbirth, and how improved methods of screening may be developed and 
evaluated. 
 
1.1 Epidemiology of stillbirth 
Stillbirth is defined as delivery of a baby in the perinatal period which fails to show any signs of life. 
The definition of the start of the perinatal period varies between countries. In the USA it is 20 weeks 
of gestational age (wkGA) and in the UK it is 24wkGA.2 The rate of stillbirth in high income countries 
varies from 1.3 per 1,000 to 8.8 per 1,000, with an average of 3.5 per 1,000.1 The clear majority of 
stillbirths in high income countries are the result of intra-uterine fetal death prior to the onset of 
labour (antepartum stillbirth).2 Deaths occurring during labour (intrapartum stillbirths) account for 5-
10% of all stillbirths in high income countries but account for a much larger proportion of losses in 
low and middle income countries (LMIC).4 A range of maternal characteristics have been associated 
with the risk of stillbirth. One of the most systematic and methodologically sound analyses of such 
risk factors was performed by the NICHD's Stillbirth Collaborative Research network.5 Their analysis 
of risk factors identifiable at the start of pregnancy is tabulated (Table 2). 
 
1.2 Causes and classification of stillbirth 
Aside from the sub-division of stillbirths into intrapartum and antepartum, losses can also be 
classified according to the presumed cause. However, this process is complicated by the fact that 
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relatively few losses have a completely understood cause of death. The remainder have varying 
degrees of uncertainty in the mechanism(s) leading to death. This is illustrated in Figure 1 in relation 
to ascribing cause of death in the presence of a range of maternal medical conditions. 
A diverse – if not bewildering – array of classification systems have been developed.1 One of the 
main characteristics which determines variation between the systems is the extent to which they 
will attribute a given associated condition or finding as being the cause of death. For example, an 
unexpected and unexplained stillbirth of an infant at 39 weeks where the baby's birth weight was on 
the 2rd percentile for sex and gestational age might be defined as unexplained in one classification 
system and as being due to fetal growth restriction (FGR) in another. In a sense, both classifications 
are correct. The actual cause of death is unknown, hence the loss is strictly unexplained. However, it 
is known that birth weight <3rd percentile is associated with a 10-fold risk of stillbirth at term.6 
Hence, it is very likely that the baby's death was related to its size. The subject of classification of 
stillbirth is reviewed in detail elsewhere.7 
In the context of screening, one of the key associations for stillbirth is poor fetal growth. It is 
estimated that between 30 and 50% of stillbirths are associated with low birth weight percentile, 
and this is assumed to reflect  FGR, which is in turn presumed to be related, in a large proportion of 
cases, to placental dysfunction.2 This association is important in the context of screening, as a 
number of tools exist to quantify both fetal growth and placental function. 
 
2. Screening for stillbirth 
The first element of screening is to differentiate a population into those at high risk of the condition 
and those at low risk. The analysis and interpretation of screening statistics can be complicated. 
Particular problems in the context of stillbirth are as follows. 
(i) stillbirth is the end result of diverse pathological processes. Hence, no one test is likely to be 
highly sensitive for the condition overall. 
(ii) stillbirth can occur across the whole range of gestational age. As the primary means to prevent 
stillbirth is to deliver the baby, the consequences of inappropriate intervention differ profoundly: at 
24 weeks outcomes are generally extremely poor, whereas at 40 weeks, outcomes are generally 
extremely good. 
(iii) stillbirth is relatively uncommon, hence, any sub-type of stillbirth is less common still. For 
example, if 40% of stillbirths are due to FGR and the risk of stillbirth in a country is 4 per 1,000, the 
absolute risk of stillbirth associated with FGR is 1.6 per 1,000. Normally, a test with a positive 
likelihood ratio of 20 would be regarded as an excellent screening test. However, the positive 
predictive value of this test in such a population would be about 3%. Consequently, 97% of screen 
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positive women would not experience the event of interest. It follows, therefore, that if an 
intervention based on such a test caused any harm to false positives, that a programme of screening 
and intervention would be likely to cause harm despite a strong screening test and an effective 
intervention. 
 
3. Maternal risk factors 
The maternal characteristics which are associated with the risk of stillbirth have been tabulated 
(Table 2).  However, collectively, these associations explained just 19% of the variability in the risk of 
stillbirth. Hence, programmes of screening and intervention which focus on maternal risk factors will 
have a relatively limited capacity to reduce the numbers of stillbirth. Another key element of 
maternal risk are the associations with gestational diabetes mellitus (GDM). There are a series of 
maternal characteristics which place a woman at increased risk of GDM (Table 3). A recent detailed 
review of a representative sample of unexpected stillbirths of normally formed infants at term in the 
UK, conducted by the national perinatal mortality surveillance system, MBRRACE-UK, found that 
failure to screen for GDM was one of the three most common potentially preventable characteristics 
observed which might have resulted in the loss being avoided.8 
 
3.1 Clinical factors associated with stillbirth risk 
Reduced fetal movements (RFM) is one of the key symptoms associated with the risk of stillbirth. 
This subject has been reviewed in detail elsewhere.9 Failure of medical and midwifery staff to 
respond appropriately to RFM was one of the other major potentially preventable causes of stillbirth 
in the MBRRACE-UK review described above.8 The RCOG in the UK has issued a guideline for the 
management of women who present with reduced movements.10 Another major symptom 
associated with stillbirth risk is antepartum haemorrhage. In the absence of placenta praevia or 
cervical pathology, this is likely to represent bleeding from the placenta, and may be a harbinger of 
later abruption. Finally, acquired disorders of pregnancy (such as GDM or pre-eclampsia) could be 
associated with maternal symptoms. Management is based on specific testing for the condition in 
question. 
 
3.2 Response to women with symptoms associated with stillbirth risk 
At preterm gestational ages, fetal monitoring is indicated. Generally, the first line of assessment is 
cardiotocography (CTG, also called a non-stress test in the USA). Interestingly, the RCOG Guideline 
on RFM does not recommend computerised CTG,10 which utilises objective analysis of the trace, 
including computerised assessment of beat to beat variability. However, the Cochrane reviews 
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indicate no benefit of using non-computerised CTG (and a trend towards harm) compared with using 
nothing, and a reduced risk of perinatal death using computerised CTG analysis compared with non-
computerised CTG (see Smith 2015, for review).11 Hence, computerised CTG is a reasonable first 
step. The next level of assessment is an ultrasound scan. This is done if there are other risk factors 
present, but will also be done in low risk women who are presenting with their second (or greater) 
episode of RFM. The key evidence-based measurement in high risk pregnancies is Doppler flow 
velocimetry of the umbilical artery. However, generally, fetal biometry and amniotic fluid 
measurement would also be performed, sometimes with additional Doppler measurements (middle 
cerebral artery). The evidence base supporting these supplementary measurements is poor: this is a 
key area for further research and multiple recommendations of the prioritisation exercise for 
stillbirth research touched on this area. 
 
At term, induction of labour should be considered for women presenting with RFM. At 37-38 weeks, 
induction is still associated with increased risks of perinatal morbidity and should only be offered if 
fetal assessment is non-reassuring, there are other risk factors or if there have been multiple 
episodes of RFM. However, perinatal outcome is optimal at 39-41 weeks and induction should be 
considered for any women presenting with RFM at ≥39 weeks. Epidemiological evidence exists that 
universal induction at 39 weeks would reduce overall rates of stillbirth.12 However, for women with a 
single episode of RFM, who have no other risk factors, and who want to avoid intervention, it is 
reasonable not to induce labour, as the absolute risk of stillbirth is likely to be <1%. The basis for this 
statement is that the background risk of stillbirth at term is 1-2 per 1,000 and it is unlikely that a 
single episode of RFM in an otherwise low risk women is associated with a >5-fold risk of stillbirth. 
 
4. Biochemical predictors of stillbirth risk 
A range of biochemical tests have been associated with the risk of stillbirth. Most of these are 
maternal blood tests but, historically, urine tests were also evaluated. Many of the associations 
described were secondary analyses of measurements made for the purposes of screening for 
unrelated conditions, such as neural tube defects and Down's syndrome. 
 
4.1 Pregnancy associated plasma protein A (PAPP-A) 
PAPP-A is a protease for insulin like growth factor binding proteins 4 and 5, and it is produced by the 
placenta. Its primary application has been for screening for Down's syndrome. However, it was 
shown that low first trimester PAPP-A was associated with stillbirth risk and that the association was 
due to losses related to placental dysfunction.13;14 A systematic review concluded that PAPP-A was a 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
"good predictor of stillbirth related to placental dysfunction disorders".15 In the UK, an RCOG 
Guideline recommends methods for further monitoring of women found to have low PAPP-A in the 
first trimester of pregnancy.16 
 
4.2 Alpha fetoprotein (AFP) 
AFP is a fetal oncotic protein. High maternal serum levels are associated with structural fetal 
anomalies (neural tube defects and abdominal wall defects) and low levels are associated with 
Down's syndrome. High levels in the second trimester are associated with the risk of stillbirth in 
normally-formed babies, but the associations are stronger for losses occurring at extreme preterm 
gestational ages.17 Hence, intervention to prevent such losses is problematic. The association is 
thought to be related to abnormal permeability of the placenta, hence increased passage of the 
protein across the placental barrier. Interestingly, unexplained raised maternal serum AFP is 
associated with a diverse series of abnormalities on subsequent placental pathological examination 
where the pregnancy was complicated.18 
 
4.3 Others 
A range of other biochemical tests have been associated with the risk of FGR and stillbirth. Some of 
these were in widespread use prior to the advent of ultrasound, such as measurement of oestrogens 
in maternal urine. Others have been more recently identified as potential screening tests for pre-
eclampsia, in particular pro- and anti-angiongenic proteins circulating in the mother’s blood, such as 
PlGF, sFlt-1, and eEng. Studies have described some promising associations with the angiogenic 
regulators.19 However, the relative rarity of stillbirth (compared with preeclampsia and preterm 
birth) make it a more difficult subject to address. Cohort studies have to be larger in order to be able 
to detect associations. Moreover, if a measurement has a positive likelihood ratio of 10, which 
would usually be regarded as a good screening test, it would only have a positive predictive value of 
<5%, and much lower still if performed later in pregnancy. 
 
Biochemical tests have great potential as a screening tool for stillbirth when combined with 
ultrasound. However, any such potential will not be adequately evaluated unless studies are 
sufficiently powered to detect associations. Moreover, interventional studies will present huge 
challenges and will require addressing significant methodological considerations (see below). 
 
5. Ultrasonic assessment of stillbirth risk 
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The first use of ultrasound to estimate the weight of the fetus was described in 1975.20 
Subsequently, multiple other methods were described to assess fetal well-being, including 
biophysical measurements (activity, breathing movements, tone and liquor volume) and ultrasonic 
Doppler flow velocimetry of fetal and utero-placental arteries and veins. Research focused on both 
the diagnosis of fetal compromise in women who had presented with complications and/or those 
known to have risk factors, and also on trying to identify which apparently low risk women had 
occult fetal compromise. The body of work quickly led to RCTs of universal screening of low risk 
women using late pregnancy ultrasound. A meta-analysis of these trials (latest version is Bricker et al 
201521 including data from a total of 34,980 women recruited to 13 trials), reported no maternal or 
fetal benefit of screening. A previous version of this meta-analysis (which had very similar 
conclusions) led NICE to conclude in their 2008 Guideline on Antenatal Care22 that women should 
not have routine late pregnancy ultrasound scans. 
 
In the same Guideline, NICE indicated that further studies on the diagnostic effectiveness of 
universal ultrasound as a screening method in the general population should be considered a 
priority. It may seem counterintuitive that NICE would declare universal screening to be ineffective 
but then to propose further studies on the diagnostic effectiveness of the screening test. This 
apparent anomaly is explained by closer examination of the studies included in the meta-analysis. 
Ultimately, all meta-analyses, however appropriately conducted, are only as good as the trials 
included. Issues with the 13 trials in the Cochrane review are as follows: (i) the individual trials used 
different definitions of screen positive, (ii) none of the definitions had been evaluated in a level 1 
study of diagnostic effectiveness prior to being employed in the screening study, i.e. all of the 
individual interventional studies were designed and conducted in the absence of high quality 
quantitative information about the performance of the screening test, (iii) none of the trials had a 
standardised intervention for those who screened positive, other than to reveal the test or to 
perform further scans. Finally, even the meta-analysis itself is under-powered. The 2016 Lancet 
Ending Preventable Stillbirth Series reported sample size calculations for trials of screening and 
intervention for stillbirth. These looked at the statistical power assuming very optimistic values of 
screening test performance (5% of the population identified with a positive likelihood ratio of 10) 
and intervention (50% reduction) based on the incidence of stillbirth (1 in 200). The sample size 
required (90% power, alpha 0.05, two sided) was 131,000.1 Hence, the meta-analysis has only about 
a quarter of the sample size required for even a very good screening test coupled with a highly 
effective intervention. Consequently, despite the fact that ultrasound has been used for >40 years to 
assess fetal well-being, and despite the fact that it is the primary method for assessing and 
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monitoring high risk pregnancies, there is an absence of evidence in relation to its utility in screening 
low risk women.  
Universal ultrasound has been assessed as a means of detecting small for gestational age (SGA) 
infants in a level 1 study of diagnostic effectiveness (i.e. where the result of the research scans was 
blinded) including ~4,000 first pregnancies.23 The rate of detection of SGA infants was 20% with 
selective use of ultrasound and 57% with universal scanning. However, for every one additional true 
positive result, there were two additional false positives with universal scanning. Moreover, of a 
range of ultrasonic indicators of FGR, only one differentiated between SGA infants and the risk of 
perinatal morbidity. Fetuses which were SGA on scan and had reduced growth velocity of the 
abdominal circumference (compared with the 20 week scan) were at increased risk of morbidity 
compared with normal sized fetuses, whereas SGA was not associated with the risk of morbidity if 
the growth velocity was normal. A meta-analysis has also demonstrated that high resistance 
patterns of Doppler flow velocimetry in the uterine arteries in mid-gestation are a good predictor of 
stillbirth related to placental dysfunction.15 However, the studies revealed the result of the scan, 
which complicates assessment of the association. 
Many private ultrasound providers have started offering late pregnancy ultrasound scans. There is, 
therefore, ad hoc screening at present with very little evidence regarding the balance of risks and 
benefits. Late pregnancy ultrasound has the potential to cause harm. False positive diagnoses can 
lead to unnecessary intervention and, in particular, early term delivery. While this is a valuable and 
evidence based intervention in certain contexts, such as pre-eclampsia, infants born at 37-38 weeks 
are at increased risk of short term morbidity,24 and even have poorer achievement at school.25 
Hence, ad hoc screening and intervention has the potential to cause short and long term harm 
through iatrogenic late preterm and early term birth. This has recently been recognised in France, 
where routine ultrasound was implemented in the absence of supportive evidence. Screening did 
not appear to confer any benefit, but false positive diagnosis of SGA was associated with a greater 
than 3-fold increase in the risk of medically-indicated preterm birth.26 This does not indicate that 
universal screening is futile. However, these findings underline the importance of understanding 
what elements of prenatal ultrasonic assessment of the fetus in a low risk pregnancy are informative 
of risk, and what interventions can be applied to mitigate the risk without causing harm.  
 
6. Interventions to prevent stillbirth 
6.1 Medical interventions 
6.1.1 Aspirin 
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Low dose aspirin has been widely evaluated as a method for preventing placentally-related 
complications in pregnancy and, in particular, pre-eclampsia. Aspirin acts by irreversibly inhibiting 
the enzyme cyclo-oxygenase (COX), which is a key point in the biochemical synthesis of prostanoids, 
including thromboxane. Aspirin selectively blocks platelet prostanoid production as they lack a 
nucleus and cannot synthesise further COX following the irreversible binding with aspirin. The 
Cochrane review contains 14 trials containing 33,098 women, and demonstrates an 14% reduction in 
the risk of stillbirth or neonatal death.27 Hence, aspirin should be considered for all women at risk of 
stillbirth. Typically, it would be started at 12 weeks and discontinued at 36 weeks. There is 
preliminary evidence from the pre-eclampsia literature to suggest that starting the treatment prior 
to 16 weeks may be associated with greater risk reduction.28 
 6.1.2 Low molecular weight heparin 
Given the success of aspirin and given some published associations between maternal thrombophilia 
and stillbirth risk, many groups have considered the use of LMWH as a preventative treatment for 
women at increased risk of stillbirth. It is regarded as a strongly indicated therapy in some situations, 
such as anti-phospholipid syndrome, where it has the additional benefit of reducing the risk of 
maternal venous thrombo-embolism. A series of small trials appeared to show a benefit of the 
treatment on perinatal outcome.29 However, a subsequent multicentre study demonstrated no 
beneficial effect of LMWH.30 A caveat to this is that even that study was only powered to detect very 
major effects of LMWH. The confidence intervals around the effect from the trial include reductions 
in stillbirth risk which would be regarded as clinically significant. The current status of LMWH is, 
therefore, that it’s use should primarily be considered to prevent maternal venous thrombo-
embolism and that further studies are required before its use is recommended for the primary aim 
of preventing fetal complications. 
 
6.1.3 Nitric oxide donors and selective phosphodiesterase inhibitors 
Nitric oxide, a gaseous mediator of smooth muscle relaxation, is thought to have a key role in the 
control of placental development, with a deficit of nitric oxide effects postulated to be a 
determinant of abnormal placentation.31 This has led to studies evaluating methods for increasing 
nitric oxide. Broadly, these fall into two categories: (i) nitric oxide donors, and (ii) selective 
phosphodiesterase inhibitors. Many nitric oxide donors have been developed for treatment of 
cardiovascular disease, such as angina and heart failure. A number of studies have evaluated nitric 
oxide donors in high risk populations. These have generally been small scale single centre studies 
and some have generated positive results.32;33 However, further large scale multicentre trials are 
required prior to introduction of these agents in the management of high risk women. Selective 
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phosphodiesterase inhibitors were first developed for cardiovascular applications. But early 
experience in healthy volunteers led to an unanticipated effect on male erectile function, and a 
range of these drugs is available for erectile dysfunction. The best known is sildenafil citrate (known 
commercially as Viagara), and the evidence supporting a beneficial effect of this drug in the context 
of early onset FGR has been reviewed.34 Currently, a multicentre RCT is in process, STRIDER, which 
seeks to assess the effect of sildenafil citrate in pregnancies complicated by early onset severe FGR. 
The field may also develop into the evaluation of other selective PDE inhibitors with longer half-life, 
and the use of the drug in pregnancies at high risk of FGR by their screening results, but prior to the 
disease onset.  
 
6.1.4 Others 
A range of other specific therapies exist, which are at various stages of evaluation but are not likely 
to be in routine clinical use in the very near future. These include the use of supplemental oxygen35 
and gene therapy.36 Both of these approaches face significant logistical issues. Gene therapy has 
been evaluated in animal models and is currently being assessed for acceptability and feasibility in 
the context of severe, early onset FGR.  
 
Finally, optimal management of co-existing medical conditions is an indirect way to reduce the risk 
of stillbirth associated with maternal disease. The obvious example is diabetes mellitus, both 
gestational and pre-existing. The risk of perinatal mortality reduces with better control. Although 
diabetes is the obvious example, it is plausible that optimal medical therapy would improve perinatal 
outcome with other maternal medical conditions, such as thyroid disease, connective tissue 
disorders etc. 
 
6.2 Delivery to prevent stillbirth 
At present, the only intervention which has a major effect on the risk of stillbirth is delivery. The 
effect of this clearly depends on (i) the background risk of stillbirth, and (ii) the gestational age, as 
GA is the major determinant of the risk of neonatal death. At term, the risk of neonatal death is 
extremely low, particularly following exclusion of deaths due to anomalies. However, the weekly risk 
of stillbirth is stable from 24 onwards and then rises at term and postterm. Combining analysis of 
declining risk of neonatal death and increasing and cumulative risk of stillbirth, it has been estimated 
that the risk of perinatal death is lowest at around 39 weeks.12 Hence, one approach to preventing 
term stillbirths would simply be to induce labour in all women at 39 weeks. This approach is 
supported by a Cochrane review, which indicates that routine induction of labour at term and post 
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term reduces the risk of perinatal mortality by ~70%.37 However, most would feel that this level of 
intervention would be excessive in relation to the number of deaths prevented. Nevertheless, this 
background should inform attitudes in general. If a woman feels strongly that she should be induced 
at 39 weeks or later, it is probably not unreasonable to agree to the request assuming the healthcare 
system is sufficiently well resourced. Furthermore, a low threshold for induction of labour should be 
applied to women with concerning symptoms or investigations. If a woman presents with reduced 
fetal movements (RFM) at 34 weeks, induction of labour would only be considered if there were 
confirmatory tests indicating other concerns. However, at 39 weeks and beyond, it would be entirely 
reasonable to induce labour for RFM. This would be especially the case if the woman actively wanted 
induced, and it would be appropriate if the woman was neutral and expressed the sentiment of so 
many “I just want what is best for my baby”. However, many women are keen to avoid induction. In 
such cases, an open discussion is required. Women who decline induction can be reassured that, 
with a single episode of RFM, no associated risk factors, and reassuring monitoring, the absolute risk 
of a stillbirth remains low. It is essential in all these discussions that the woman’s own attitudes and 
preferences are a foundation for the discussion. A key element for any such discussion would be to 
contradict the misconception that induction of labour increases the risk of caesarean section. A 
systematic review indicates that it results in a lower risk of caesarean delivery.38 Moreover, a recent 
RCT has shown no increase in the risk of caesarean section when labour was induced at 39 weeks in 
a group of women with a high background risk of caesarean (nulliparous women aged 35y or 
greater).39 
 
6.3 Modifying maternal risk factors for stillbirth 
A number of the maternal characteristics associated with stillbirth risk are potentially modifiable. 
Numerous studies have demonstrated higher rates of stillbirth among smokers, and a causal 
association is plausible. It follows, therefore, that smoking cessation is likely to reduce the risk of 
stillbirth. Given the problems of conducting RCTs of interventions to prevent stillbirth (see below), it 
is unlikely that there will ever be level 1 evidence to support the use of smoking cessation as a 
means to prevent stillbirth. Nevertheless, given the background and given that this represents an 
absence of evidence, rather than evidence of absence, recommending that mothers participate in 
smoking cessation would be an appropriate approach. Similarly, raised body mass index is both 
directly associated with stillbirth in epidemiological studies and is also a risk factor for a cause of 
stillbirth, namely, GDM. Weight reduction should be considered for women who are obese and are 
planning pregnancy. Dieting through calorific restriction is controversial in pregnancy. However, 
women who are obese should be referred to a dietician and approaches which might improve 
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outcomes include reducing quantities of sugar intake, controlling portion sizes, eating more fresh 
fruit and vegetables, and the maintenance of healthy levels of activity through pregnancy. 
A number of epidemiological studies have shown associations between maternal sleep position and 
the risk of stillbirth. These have demonstrated increased risks of stillbirth with supine sleep position, 
and it is speculated that this may be due to reduced blood supply to the uterus through caval 
compression (i.e. a pressure effect of the gravid uterus on the inferior vena cava). Further studies 
aiming to confirm or refute the association are in progress. If these confirm the association with 
maternal sleep position, there may be a case for a public health campaign to modify maternal sleep 
position as a means to reduce stillbirth risk. This is analogous with sudden infant death syndrome: 
epidemiological studies demonstrated an association with prone infant sleeping positon and SIDS, 
and a public health campaign was followed by an extraordinarily rapid decline in rates of SIDS in the 
UK.40  
 
7. Evaluating novel methods for screening and prevention of stillbirth.  
Despite huge expenditure of time and resources, there is no clear approach to screening women for 
stillbirth risk. Numerous studies have described possible methods for screening, including 
biochemical tests and ultrasound scans. However, none has been clearly shown to be effective in 
randomised controlled trials. The negative results of the trials do not necessarily indicate that 
ultrasound is futile. As discussed above, there are multiple issues in relation to the meta-analysis of 
RCTs of universal ultrasound. It is essential, therefore, that any future trials learn the lessons from 
previous trials and address new methods of screening using a methodologically rigorous approach. 
Key elements in designing new RCTs to prevent stillbirth are as follows: (i) the eligible population, (ii) 
the screening test to be employed and its diagnostic effectiveness, (iii) the timing of randomisation, 
namely, before or after application of the screening test, (iv) the intervention, (v) the control group, 
(vi) the primary and secondary outcomes, (vii) the sample size, (viii) the possibility of randomising at 
the level of hospitals, e.g. using a cluster RCT or stepped wedge RCT, (ix) the potential use of an 
adaptive trial design, (x) whether an initial smaller scale feasibility study is required, and (xi) the 
feasibility of the study, including manpower, skills mix, and quality assurance of the screening test. 
Many of these issues have previously been discussed in more depth elsewhere.41 
 
8. Summary 
Stillbirth in the single major determinant of perinatal death. In high income countries, ≥90% follow 
death of the baby prior to the onset of labour, and in this setting typical absolute rates are 3-4 per 
1,000. Stillbirth is the end result of diverse processes, hence a single perfect screening test is unlikely 
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to be developed. Currently, women are assessed for their risk of stillbirth at the time of first 
attendance for antenatal care, and then are re-assessed during the pregnancy either at routine visits 
or when they present with symptoms which are associated with increased risk of stillbirth (such as 
reduced fetal movements). A range of methods have been developed to estimate the risk of stillbirth 
and associated conditions (such as FGR). Currently, investigations such as ultrasound are only 
applied to women who have risk factors or attend with complications. However, the possible utility 
of universal ultrasound has been poorly evaluated. About one third of all stillbirths occur at term and 
these are, potentially, the most readily preventable as there is a safe and effective intervention, 
namely, induction of labour, which reduces the risk of perinatal death by 70%. A key challenge is 
how to identify the women at increased risk of stillbirth and who would benefit from this 
intervention, from the general healthy population. In this way, losses could be prevented without 
causing unacceptably high rates of intervention.  
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Legend for Figure. 
 
Figure 1. Representation of the continuum of uncertainty in ascribing cause for stillbirth, 
using the example of losses associated with maternal medical conditions. ALT denotes 
alanine transaminase; GA denotes gestational age. Reproduced with permission from a 
report of an NICHD workshop (Reddy et al., Obstet Gynecol 2009;114:901-914).  
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*Studies of particular importance to the current topic. 
Practice points 
 Maternal risk factors do not perform well as a screening test for stillbirth. Many stillbirths 
occur to low risk women 
 Common issues with quality of care in relation to stillbirth prevention include failure of 
effective screening or treatment of GDM, reduced fetal movements, or poor fetal growth 
 Non-computerised antenatal cardiotocography has little role in assessing fetal well being, 
and may provide false reassurance about stillbirth risk in women presenting with reduced 
movements 
 Induction of labour can safely be considered from 39 weeks onwards, even in relatively low 
risk women. It will prevent subsequent stillbirth, and is not associated with an increased risk 
of caesarean delivery. 
 Women at risk of stillbirth should be treated with low dose aspirin from 12 to 36 weeks. Low 
molecular weight heparin should primarily be used to prevent maternal thrombo-embolism 
and its use to prevent stillbirth will largely be confined to randomised controlled trials 
 
*Practice Points
Research agenda 
 Design, feasibility and optimal design of an RCT of universal ultrasound, and the effect of 
universal ultrasound scanning 
 The best ultrasonic markers of likely intra-uterine fetal death in women presenting with 
complications 
 The ability of biomarkers to differentiate between women with normal and abnormal 
placental function 
 The relationship between placental pathology and adverse pregnancy outcome, and 
methods for diagnosing specific placental pathological processes in the antenatal period 
(e.g. blood tests for recognised placental disease processes) 
 The mechanisms leading to placental dysfunction 
 
*Research Agenda
Multiple choice questions 
 
Question 1. 
In relation to the epidemiology of stillbirth: 
(a) the absolute risk of all cause stillbirth in high income countries is <1 in 1000 
(b) globally, i.e. combining low, middle and high income countries, ≤10% of stillbirths follow 
intrapartum intra-uterine fetal death 
(c) maternal risk factors explain more than 50% of the variation in stillbirth risk in the USA 
(d) more than 90% of stillbirths are associated with fetal growth restriction 
(e) if a post mortem has been performed, a minority of stillbirths have a clear and well-
defined cause of death 
Answers: (a) F (b) F (c) F (d) F (e) T 
Explanation of answers: (a) The average rate for a high income country is 3-4 per 1,000 and 
all rates fall within the range 1-9 per 1,000 (b) In high income countries, intrapartum 
stillbirth does account for 5-10% of all stillbirths. However, the proportion is much high in 
low and middle income countries and 98-99% of all stillbirths occur in such countries (c) 
Overall, it is estimated that <20% of the variation in stillbirth risk is explained by maternal 
characteristics.  (d) The exact proportion of stillbirths estimated to be due to growth 
restriction depends on the method used, but generally it is in the region of 30-50%. Hence, 
better screening for growth restriction would only impact on a minority of stillbirths. (e) The 
cause of most stillbirths is not known. There are many associations, particularly in relation 
to placental histopathology. However, many of these are also seen in completely normal 
pregnancies. Hence, the actual cause of death is not known for many stillbirths. 
 
Question 2 
In relation to biochemical markers of stillbirth risk: 
(a) low levels of PAPP-A in the first trimester are associated with an increased risk of 
stillbirth due to placental causes 
(b) the use of urinary oestriol was shown to be ineffective in an appropriately powered 
randomised controlled trial 
*MCQs
(c) elevated levels of maternal serum AFP are associated with stillbirth due to neural tube 
defects and anterior abdominal wall defects, but are not predictive of the risk of loss in 
normally formed infants 
(d) low levels of PAPP-A in the third trimester have been shown to be associated with the 
risk of unexplained stillbirth 
(e) measurement of the sFlt-1/PlGF ratio should be performed in women presenting with 
reduced fetal movements 
Answers: (a) T (b) F (c) F (d) F (e) F 
Explanation of answers: (a) A PAPP-A level of <0.4 multiples of the median is associated 
with an increased risk of stillbirth and the majority in this group are associated with fetal 
growth restriction, placental abruption or preeclampsia  (b) The use of biochemical tests of 
placental function were both introduced and withdrawn in the absence of clear evidence of 
effectiveness (or ineffectiveness) (c) Raised msAFP is associated with these structural 
abnormalities but elevated second trimester levels are also associated with an increased risk 
of non-anomalous stillbirth, particularly at early gestational ages and associated with 
placental causes  (d) the data on PAPP-A and stillbirth relate to first trimester measurement, 
and there is an absence of evidence in relation to late pregnancy measurements (e) the  
sFlt-1/PlGF ratio has been described as a test for maternal pre-eclampsia, but there is 
limited evidence regarding its association with stillbirth. 
 
Question 3. 
In relation to induction of labour: 
(a) Induction can safely be performed at any stage of pregnancy from 37 weeks onwards 
(b) Level 1 evidence indicates that induction of labour results in a 10-15% reduction in the 
risk of caesarean delivery 
(c) Level 1 evidence indicates that induction of labour at term and postterm reduces the risk 
of perinatal mortality by ≥50% 
(d) Level 1 evidence indicates that, among nulliparous women aged 35 and above, routine 
induction of labour had no effect on the risk of caesarean delivery. 
(e) It should not be considered in a woman presenting at 40 weeks gestational age with her 
first presentation with reduced fetal movements. 
Answers: (a) F (b) T (c) T (d) T (e) F 
Explanation of answers: (a) Delivery at 37-38 weeks is referred to early term. It is associated 
with increased risks of short term and long term complications. Hence, it is generally only 
indicated if the balance of risks of expectant management exceed these risks. (b) Although 
induction of labour is associated with higher rates of caesarean delivery in observational 
studies, the reverse is apparent in RCTs. This suggests that the observational associations 
are due to confounding by the indication for induction. (c) This is a key finding of the meta-
analysis. The explanation is that once a baby is delivered it is no longer at risk of stillbirth. 
Hence, shortening the pregnancy reduces the risk of stillbirth. However, from 38 weeks 
onwards, there is no further decline in the risk of neonatal death with advancing gestational 
age. (d) This was the key finding of the 35/39 trial, published in NEJM 2016. (e) Elective 
induction (i.e. without a medical indication) can be considered from 39 weeks onwards. 
Reduced fetal movements commonly precede stillbirth. Hence, induction of labour should 
be offered to women who present with reduced fetal movements from 39 weeks onwards.  
 
Question 4. 
In relation to universal late pregnancy ultrasound: 
(1) Level 1 evidence indicates that universal late pregnancy ultrasound reduces the risk of 
perinatal morbidity related to fetal growth restriction 
(2) The meta-analysis of RCTs of universal late pregnancy ultrasound has >90% power to 
detect a 50% reduction in the risk of stillbirth in screen positive women, assuming a positive 
likelihood ratio of 10 or greater 
(3) Has been implemented in some countries despite clear positive evidence of clinical 
effectiveness 
(4) Could not plausibly cause harm, directly or indirectly. 
(5) If performed at 28 and 36 weeks, increases the detection of SGA infants by about 3-fold 
compared with selective use of ultrasound. 
Answers: (a) F (b) F (c) T (d) F (e) T 
Explanation of answers: (a) The current meta-analysis of RCTs fails to demonstrate any 
benefits of universal ultrasound. (b) The current meta-analysis is too small to be adequately 
powered to detect a reduction in perinatal death with plausible estimates of screening test 
and interventional effectiveness. (c) A number of countries have implemented universal late 
pregnancy ultrasound in the absence of trial evidence. (d) False positive diagnoses have 
significant potential to cause harm. For example, if a woman has a scan and the baby is 
wrongly diagnosed as being large for dates, she is at increased risk of emergency caesarean 
during labour. (e) A level 1 study of diagnostic effectiveness published in the Lancet is 2015 
demonstrated a 20% rate of detection with selective ultrasound and a 57% rate of detection 
with universal ultrasound. However, for every 1 additional true positive for SGA, there were 
2 additional false positives.  
 
Figure
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Table 1. Top 11 research priorities from a stillbirth priority setting partnership 
Research questions 
How can the structure and function of the placenta be assessed during pregnancy to detect 
potential problems and reduce the risk of stillbirth?  
Does ultrasound assessment of fetal growth in the third trimester reduce stillbirth?  
Do modifiable ‘lifestyle’ factors (e.g. diet, vitamin deficiency, sleep position, sleep apnea, 
lifting and bending) cause or contribute to stillbirth risk?  
Which investigations identify a fetus at risk of stillbirth after a mother believes she has 
experienced reduced fetal movements?  
Can the wider use of existing tests and monitoring procedures, especially in later pregnancy, 
and the development and implementation of novel tests (biomarkers) in the mother or in 
early pregnancy, help prevent stillbirth?  
What causes stillbirth in normally grown babies?  
What is the most appropriate bereavement and postnatal care for both parents following a 
stillbirth?  
Which antenatal care interventions are associated with a reduction in the number of 
stillbirths?  
Would more accessible evidence-based information on signs and symptoms of stillbirth risk, 
designed to empower women to raise concerns with healthcare professionals, reduce the 
incidence of stillbirth?  
How can staff support women and their partners in subsequent pregnancies, using a holistic 
approach to reduce anxiety, stress and any associated increased visits to healthcare 
settings?  
Why is the incidence of stillbirth in the UK higher than in other similar high-income 
countries, and what lessons can we learn from this? 
 
 
Text quoted verbatim from Heazell et al, 2015 (reference 3) 
Table
Table 1. Maternal risk factors for stillbirth. 
Characteristic Adjusted 
Odds ratio 
95%  
confidence interval 
Non-Hispanic black race/ethnicity 2.12 1.41 to 3.20 
Previous stillbirth 5.91 3.18 to 11.00 
Nulliparity +  previous losses at <20 weeks' 3.13 2.06 to 4.75 
Nulliparity, no previous losses 1.98 1.51 to 2.60 
Diabetes mellitus 2.50 1.39 to 4.48 
Maternal age 40 years or older  2.41 1.24 to 4.70 
Maternal AB blood type  1.96 1.16 to 3.30 
History of drug addiction  2.08 1.12 to 3.88 
Smoking  1.55 1.02 to 2.35 
Obesity/overweight  1.72 1.22 to 2.43 
Not living with a partner  1.62 1.15 to 2.27 
Multiple pregnancy  4.59 2.63 to 8.00 
 
Data from reference 5 (see publication for details of multivariate analysis and referent 
categories). Stillbirth defined on basis of ≥20 weeks gestational age threshold. 
 
Table
Table 2. Maternal risk factors for gestational diabetes mellitus 
Maternal risk factors for gestational diabetes mellitus 
Body mass index >30 kg/m2  
Previous macrosomic infant (>4.5kg) 
Previous gestational diabetes 
First degree relative with diabetes 
Ethnic origin associated with high incidence of diabetes 
 
 
Table
